Candriam S.C.A. Clovis Oncology, Inc. Transaction History

Candriam S.C.A.

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Jul 20, 2021	SELL	$5.02 - $7.05 $2.68 Million - $3.76 Million	-533,832 Closed	0 $0
Q4 2020 Jan 22, 2021	SELL	$4.13 - $6.41 $3.52 Million - $5.46 Million	-851,803 Reduced 61.47%	533,832 $2.56 Million
Q3 2020 Oct 19, 2020	BUY	$4.82 - $7.72 $420,231 - $673,068	87,185 Added 6.71%	1,385,635 $8.08 Million
Q2 2020 Jul 23, 2020	BUY	$5.69 - $9.69 $1.7 Million - $2.89 Million	298,535 Added 29.86%	1,298,450 $8.77 Million
Q1 2020 May 26, 2020	BUY	$3.77 - $11.0 $233 - $682	62 Added 0.01%	999,915 $10.2 Million
Q4 2019 Jan 21, 2020	SELL	$3.0 - $16.43 $393,810 - $2.16 Million	-131,270 Reduced 11.61%	999,853 $10,000
Q3 2019 Oct 21, 2019	BUY	$3.93 - $15.35 $90,390 - $353,050	23,000 Added 2.08%	1,131,123 $4,000
Q2 2019 Aug 01, 2019	BUY	$12.81 - $25.67 $4.18 Million - $8.38 Million	326,500 Added 41.77%	1,108,123 $16.4 Million
Q1 2019 May 02, 2019	BUY	$17.66 - $30.28 $8.63 Million - $14.8 Million	488,523 Added 166.67%	781,623 $19.4 Million
Q4 2018 Feb 14, 2019	BUY	$11.63 - $32.67 $883,880 - $2.48 Million	76,000 Added 35.01%	293,100 $5.26 Million
Q3 2018 Nov 07, 2018	BUY	$29.37 - $49.48 $619,707 - $1.04 Million	21,100 Added 10.77%	217,100 $6.38 Million
Q2 2018 Aug 14, 2018	BUY	$42.06 - $62.4 $904,290 - $1.34 Million	21,500 Added 12.32%	196,000 $8.91 Million
Q4 2017 Feb 07, 2018	SELL	$57.69 - $84.58 $2.48 Million - $3.64 Million	-43,000 Reduced 19.77%	174,500 $11.9 Million
Q3 2017 Nov 03, 2017	BUY	$67.17 - $84.81 $14.6 Million - $18.4 Million	217,500	217,500 $17.9 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.